Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Evaluating Efficacy and Safety of Berotralstat in Preventing Angioedema Attacks in Subjects With Acquired Angioedema Due to C1 Inhibitor Deficiency (AAE) (BESAFE)

18 november 2026 uppdaterad av: IRCCS Policlinico S. Donato

An Open Label, Single Arm, Explorative Trial to Evaluate Efficacy and Safety of Berotralstat in Preventing Angioedema Attacks in Subjects With Acquired Angioedema Due to C1 Inhibitor Deficiency (AAE)

The primary aim of the study is to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with Acquired Angioedema (AAE-C1-INH).

Studieöversikt

Status

Har inte rekryterat ännu

Intervention / Behandling

Detaljerad beskrivning

This study aims to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with AAE-C1-INH and to evaluate its safety profile. This is an open label single arm study. Each eligible subject who consents to participate in the study will receive 24 weeks (168 days) of oral Berotralstat (150 mg). All subjects will undergo a screening period (including a prospective AAE-C1-INH attack run- in period between 28 and 56 days) and will then enter the treatment phase. During this phase, there will be follow-up assessments (at 29, 85 and 169 days) including physical examination, vital signs assessment, blood and urine analysis, 12-lead ECG and PROMs evaluation. Details on AAE-C1-INH attacks, concomitant medications and adverse events will be collected through the course of the study.

Studietyp

Interventionell

Inskrivning (Beräknad)

16

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Palermo, Italien, 90146
        • A.O. "Ospedali Riuniti Villa Sofia-Cervello"
        • Kontakt:
    • Milan
      • Milan, Milan, Italien, 20157
      • San Donato Milanese, Milan, Italien, 20097
        • IRCCS Policlinico San Donato
        • Kontakt:
    • Naples
      • Naples, Naples, Italien, 80131
        • Università degli Studi di Napoli Federico II
        • Kontakt:
    • Padua
      • Padova, Padua, Italien, 35128
        • Azienda Ospedale-Università di Padova
        • Kontakt:
    • Rome
      • Roma, Rome, Italien, 00133
    • Turin
      • Torino, Turin, Italien, 10128
        • AO Ordine Mauriziano di Torino
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Males and non-pregnant, non-lactating females ≥ 18 years of age

  2. Able to provide written, informed consent.

  3. Subject weight of ≥ 40 kg

  4. A clinical diagnosis of AAE is defined from the following criteria:

    • Recurrent angioedema without wheals

    • No family history of angioedema and/or C1-INH deficiency

    • C1-inhibitor activity level of <50% of normal and at least 1 of the following:

      • Age at least 40 years at reported onset of first angioedema symptoms
      • Reduced C1q level (below the lower limit of normal), recognizing that normal C1q levels do not exclude the diagnosis of AAE. Absence of a pathogenic variant in the SERPING1 gene encoding for the C1-inhibitor protein.
      • Serologic confirmation of anti-C1-inhibitor antibodies.
  5. Access to and ability to use one or more acute medications approved by the relevant competent authority for the treatment of acute attacks of HAE (icatibant, plasmaderived C1-INH).

  6. The subject must have at least 2 AAE attacks which meet all the requirements below during the run-in period of 28 days. In case of not recurrence of 2 attacks in 28 days or attacks do not meet all the requirements below, the run-in period will be extended to a maximum of 56 days from the Screening visit:

    • The attacks are unique, which is defined as an attack that does not begin within 48 hours of the end of a previous attack.
    • The attacks must include symptoms of swelling. Symptoms of swelling, in addition to visible swelling, may also include symptoms in the oropharyngeal or abdominal regions which are indicative of internal swelling.
    • The attacks are confirmed by the Investigator to be AAE attacks. Subjects will be contacted within 2 business days of the attack to discuss the attack, any queries on the entered data in the diary, as applicable.
  7. In the opinion of the Investigator, the subject is expected to adequately comply with all required study procedures for the duration of the study. The subject must demonstrate adequate compliance with all study procedures required from the screening visit, including diary recording of HAE attacks beginning at the screening visit. Women of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective method of contraception, throughout the study and for the protocol-defined period after the last dose of the investigational medicinal product (IMP). Acceptable highly effective methods include combined (estrogen- and progestogen-containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine devices (IUDs), intrauterine hormone-releasing systems (IUSs), bilateral tubal occlusion, vasectomized partner (provided he is the sole sexual partner), and true sexual abstinence when this is the participant's usual and preferred lifesty.

Exclusion Criteria:

  1. Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study or increases the risk to the subject by participating in the study

  2. Concurrent diagnosis of any other type of recurrent angioedema

  3. Any abnormal clinical, laboratory or urinalysis parameter at screening that, in the opinion of the Investigator or any contraindication describe in berotralstat SmPC

  4. Known hypersensitivity to the active substance of berotralstat or to any of its excipients

  5. Current treatment with any long-term prophylactic therapy intended for the prevention of angioedema attacks, unless the required washout period has been completed before the start of the run-in period. Required washout periods are as follows:

    • plasma-derived or recombinant C1 inhibitor used for long-term prophylaxis: 14 days;
    • lanadelumab: 28 days;
    • berotralstat or any other oral plasma kallikrein inhibitor: 28 days;
    • attenuated androgens (e.g., danazol): 28 days;
    • tranexamic acid: 28 days;
    • any other investigational or approved long-term prophylactic treatment for angioedema: at least 28 days, or 5 half-lives, whichever is longer.

    Use of approved on-demand (rescue) therapies for the treatment of acute angioedema attacks (e.g., icatibant or plasma-derived C1 inhibitor) is permitted throughout the study, including during the run-in period and the treatment period, according to standard clinical practice.

  6. Pregnant women

  7. Patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) in alignment with SmPC requirement

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Berotralstat Treatment

Patients will receive capsules of oral Berotralstat for 24 weeks until the end of the study.

Patients will receive capsules of oral Berotralstat for 24 weeks until the end of the study.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Berotralstat Effectiveness
Tidsram: Up to 24 weeks.

The primary objective of the study is to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with AAE-C1-INH. The primary efficacy endpoint is the change in the monthly HAE attacks rate, from week 1 to week 24 of treatment compared to attack rate during the run-in period.

Up to 24 weeks.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Berotralstat Safety
Tidsram: Up to 24 weeks.

The safety objective is to evaluate the proportion of patients with adverse events (AEs) including treatment-emergent serious adverse events (TESAEs).

Up to 24 weeks.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Andrea Zanichelli, PhD, MD, IRCCS Policlinico S. Donato

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

15 november 2026

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 december 2027

Studieregistreringsdatum

Först inskickad

19 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

18 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • BESAFE

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera